A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA\(^{-/-}\) and mutant-p53

Denada Dibra\(^1\)\(^*\), Xueqing Xia\(^2\), Mihai Gagea\(^3\), Guillermina Lozano\(^1\), Shulin Li\(^2\)\(^*\)

1 Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 2 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 3 Department of Veterinary Medicine & Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America

\(^*\) sl4@mdanderson.org (SL); ddibra@mdanderson.org (DD)

Abstract

Spondyloarthropathies, the second most frequently occurring form of chronic inflammatory arthritis, affects young adults in particular. However, a proper model with which to study the biology of this disease and to develop therapeutics is lacking. One of the most accepted animal models for this disease uses HLA-B27/Hu-\(\beta\)2m transgenic rats; however, only 30%-50% of male HLA-B27/Hu-\(\beta\)2m rats develop spontaneous, clinically apparent spondylitis and have a variable time until disease onset. Here, we report a high-incidence, low-variation spontaneous mouse model that delineates how the combination of inflammatory cytokine interleukin-27 (IL-27) signaling deficiency and mitogenic signaling (mutant p53\(^{R172H}\)) \textit{in vivo}, leads to bone loss in the vertebral bodies and ossification of the cartilage in the intervertebral discs. In this human disease–like mouse model, bone loss and pathogenic bone development are seen as early as 4 months of age in the absence of inflammatory aggregates in the enthesis or intervertebral disc.

Introduction

Spondyloarthropathies display a unique pathology in their progression from an initial inflammatory phase to an osteoproliferative/ankylosing phase. Generating an animal model that replicates pathological changes of human disease is crucial to developing therapeutics. One of the best animal models described is the rat HLA-B27 model [1]. Although this models has all three phenotypes of the disease, namely inflammatory aggregates, bone loss, and bone gain, only 30%-50% of males develop these phenotypes the time until disease onset and the severity of lesions vary among individuals [1]. IL-23 is also a culprit in this disease; others have shown that \textit{in vivo} expression of IL-23 is sufficient to phenocopy the human disease, with development of enthesitis and enthesal new bone development [2].
While interleukin-27 (IL-27) which is in the same family as IL-23, plays a significant role in bone remodeling and arthritis, its role in axial spondyloarthropathies in vivo has not been investigated in vivo especially in the absence of arthritic triggers [3–7]. One of the functions of IL-27 is to negatively regulate IL23, RAR-related orphan receptor (ROR) γt, and Th17 differentiation [8–10]. Interestingly, both these cytokines, IL23 and IL17 have been heavily implicated in psoriatic arthritis [11–13]. Briefly, patients with active psoriatic arthritis who had inadequate response to tumor necrosis factor inhibitors, improved signs of symptoms when treated with IL17 inhibitor [12].

P53 pathway is implicated in bone and proper skeletal development. Females that are null for p53 (p53−/−) die during embryogenesis from failed neural tube closure leading to exencephaly and anencephaly [14]. P53 also negatively regulates osteoblast differentiation and function by repressing the expression of osterix, an osteoblast-specific transcription factor [15]. Similarly, another independent study showed that osteoblast progenitor cells with deleted mdm2 (negative regulator of p53) had elevated p53 activity, reduced proliferation, reduced levels of the master osteoblast transcriptional regulator Runx2, and reduced differentiation [16]. Mutant p53 is an oncogene that promotes tumorigenesis [17]; one mechanism by which this occurs is through mutant p53 binding to wild-type p53 and attenuating wild-type p53’s transcriptional activity (otherwise known as dominant negative functions) [18]. Furthermore, p53 negatively regulates autoimmunity via the STAT3-Th17 axis [19]. Since both the IL-27 and p53 pathway are involved in bone development and remodeling and both negatively regulate IL-17, we thought to interrogate the biological significance of the integration of IL-27 and p53 pathways via genetic means in vivo. We found that IL27 signaling deficiency and a mitogenic signal such as mutant p53 converge and develop bone loss in the vertebral bodies and ossification of the cartilage in the intervertebral discs, mimicking a similar phenotype seen in patients with axial spondyloarthropathies.

Materials and methods

Genetically-engineered mice

IL27RA−/− mice (Interleukin-27 Receptor alpha) were previously donated by Dr. Frederic de Sauvage (Genentech) in a C57Bl/6 background. P53R172H+/− were donated from Dr. Lozano (C57Bl/6 and a small percentage of 129/SvJ background). The breeding strategy was as follows: IL27RA−/− P53R172H+/− mice (heterozygous for p53 R172H locus) were bred to IL27RA−/− P53R172H/− mice and subsequently genotyped for p53 status. IL27RA−/− P53+/+ mice with the p53 wild-type locus were simply labeled IL27RA−/− throughout the study, whereas IL27RA−/− P53R172H/− with p53 heterozygous containing one copy of the wild-type p53 locus and one copy of the mutant knock-in p53 were labeled IL27RA−/− P53R172H/+ . Littermates were included controls. IL27RA−/− P53R172H/H− mice were not included in the study. The cohorts were monitored over time. Genotyping was performed as described below for both p53 and IL27RA. For the cohort studies, mice were euthanized and necropsied when they reached euthanasia criteria or at the indicated time points. Research procedures of all animals were performed according with research protocols approved by the IACUC at MDACC. Mice were euthanized via CO2 followed by cervical dislocation. During imaging, mice were anesthetized with isoflurane. Mice were housed at a maximum 5 mice per cage in a pathogen-free facility, and fed standard chow diet. Both males and females were used in our studies.

Histopathologic analysis

H&E stained tissues were examined microscopically by a pathologist at MD Anderson Cancer Center, and the severity of lesions was scored using a 0–4 grading scale as follows: grade 0 = no
histologic lesion; 1 = minimal or rare lesion (or the lesion affects less than 10% of the tissue); 2 = mild or infrequent lesion (or the lesion affects 10–20% of tissue); 3 = moderate or frequent lesion (or the lesion affects 20–40% of tissue); 4 = marked, extensive or severe lesion (or the lesion affects 40–100% of tissue). Photomicrographs were taken with Nikon Eclipse Ti microscope.

**Genotyping**

DNA was extracted from ear tissue, and PCR for the p53 gene was performed with use of the primer sequence as previously described by Lang et al. [18]. The presence of the p53R172 gene was confirmed by using the forward CAAGAAGAGGTCCCG TGCTG primer sequence and the reverse TTGAGCCCAGTCCACCACAT sequence. PCR primers for the absence of IL27RA were as follows: GCTTTTCGTCTCCCCGTGTC (forward) and TGAGCCAGAAAGCCAAGGA (reverse).

**Micro-CT image acquisition and analysis**

CT images were acquired as previously described [20]. Briefly, these images were acquired by using five 100-ms frames at each 1˚ rotation increment with an x-ray tube potential and current of 80 kVp and 450 μA, respectively, via an RS-9 micro-CT scanner (GE Healthcare, London, Ontario, Canada). Two adjacent image volumes were acquired with an overlap of 40% of the field of view in the axial direction and stitched together after reconstruction. Images had a nominal isotropic resolution of 91 μm and required approximately 25 minutes of scan time. The bone was visualized with use of GEHC Microview Software. All image isosurfaces were visualized and analyzed for bone mineral density (BMD) by using the same image threshold value.

**Statistical analysis**

ANOVA with Tukey as a post-hoc test was used to analyze the differences among groups. P < 0.05 was considered significant.

**Results**

We bred IL27RA−/− mice with mutant p53 heterozygous (p53R172H/+) mice to generate IL27RA−/− p53R172H/+ mice. We micro-CT scanned aged-matched mice at 12–14 months of age. Indeed, IL27RA−/− p53R172H/+ mice had significant loss of bones in the spinal column when compared with controls (Fig 1A and 1B). Aside from bone loss, these mice had significant bone growth as well (Fig 1C). Others have reported that mild to heavy infiltration of inflammatory aggregates between the vertebral bodies and intervertebral discs are the initiating events in the development of these bone lesions [21]. Surprisingly, infiltration of minimal to no inflammatory cells were detected in either the enthesis or in the intervertebral discs in our study, suggesting that a preliminary inflammatory event may not be required for the initiation or development of pathological lesions of the bone observed here (Fig 1D).

One caveat with the already well-established HLA-B27/Huβ2m rats is that these animals have low incidence of disease and variable time until disease onset [1]. To understand whether these limitations are present in the proposed IL27RA−/− p53R172H/+ mouse model, a large number of mice were examined to delineate the incidence, locations, frequency, and variability within the group. During the life of our mice, a sequential analysis of BMD (bone mineral density) utilizing the micro-CT images was conducted. van Duivenvoorde et al. [21] showed that bone loss and bone proliferation occur in two different anatomical areas, in the vertebral body and the intervertebral space, respectively. At age 2 months, no significant changes were seen in
bone loss of the spine of IL27RA$^{-/-}$ p53$^{R172H/+}$ mice, whereas significant bone loss was seen at age 4 and 8 months compared with the controls (Fig 2A). Both genders were included in our studies. Furthermore, size and mobility of the pups was normal across all genotypes. The observation that no differences in BMD were seen in the spinal column amongst different genotypes of mice at 2 months of age suggest that bone development was normal up to this age in IL27RA$^{-/-}$ p53$^{R172H/+}$ mice. Therefore, most likely the lower BMD observed in IL27RA$^{-/-}$ p53$^{R172H/+}$ mice is associated with bone loss rather than abnormal bone formation. To quantify these differences while uncoupling bone loss and bone growth, we set the measurement to cover only the vertebral body and to exclude the intervertebral disc. The same height for each vertebra was measured in all mice. Significant BMD decline was seen in IL27RA$^{-/-}$ p53$^{R172H/+}$ mice compared with the other controls starting as early as 4 months (Fig 2B). Of interest, even in the absence of IL27RA$^{-/-}$, p53$^{R172H/+}$ mice with rare inflammatory cells within the enthesis adjacent to the intervertebral discs, $^\ast$, $p<0.05$. Each dot represents an individual mouse.
Mutant-p53 and lack of IL27RA cause spontaneous spondyloarthropathies

A

B

C

D

2 month

4 month

8 month

WT

IL27RA⁻/⁻

p53⁻/⁻

IL27RA⁻⁻p53⁻/⁻

WT

IL27RA⁻/⁻

p53⁻/⁻

IL27RA⁻⁻p53⁻/⁻

WT

IL27RA⁻/⁻

p53⁻/⁻

IL27RA⁻⁻p53⁻/⁻

BMD vertebrae (mg/cm²)

n.s.

*
of the spinal column of mice at various ages were analyzed. No evident changes were seen in IL27RA−/− p53R172H/+ mice or in controls at age 2 months. Of interest, ossification of the cartilage of the intervertebral disc on both sides of the nucleus pulposus of the IL27RA−/− p53R172H/+ mice was observed in 4-month-old mice (Fig 2C). These differences were also present in 8-month-old mice. Surprisingly, even in the intervertebral disc of 4-month-old p53R172H/+ mice, some ossification of the cartilage in the intervertebral disc was observed, but not in the 8-month-old mice. Such observations suggest that mutant p53 might contribute to the ossification of cartilage, but the incidence of this phenotype becomes high only with the combination of mutant p53 and IL-27 signaling. To quantify these differences, BMD measurement on the intervertebral disc on microCT images of IL27RA−/− p53R172H/+ and control mice were performed. The same height for intervertebral disc was used across all animals analyzed. BMD loss of the adjacent vertebral body was used as a baseline for the intervertebral BMD gain calculations. Indeed, BMD gain measurements associated with histological observations (Fig 2D): BMD in the intervertebral disc of IL27RA−/− p53R172H/+ mice at ages 4 and 8 months was significantly higher than that in the control groups. Remarkably, occasional or no inflammatory cells were seen in the intervertebral discs or enthesis of these mice at any of the above-mentioned time points.

Spondyloarthropathies in patients comprise a variety of related disorders including inflammatory pathologies (albeit at a low percentage) in other non-bone-related sites such as skin, lung, kidney, and intestines [22–24]. Indeed, IL27RA−/− p53R172H/+ mice developed a few of these pathologies including chronic kidney nephropathy (7.5% incidence) (Fig 3B and 3C). Finally, 4% of IL27RA−/− p53R172H/+ mice developed neutrophilic dermatitis in the tail that progressed into the subcutaneous tissues and vertebral body of the tail characterized by local neutrophilic periosteitis and osteitis (Fig 3D and 3E). None of these phenotypes were observed in control, age-matched mice.

Discussion

There is extensive debate if and how inflammation and bone gain are coupled in spondyloarthropathies. Most of the described animal models support an inflammatory-driven process such as overexpression of human TNF, mouse TNF, transmembrane TNF, or overexpression of IL1, which develop a wide range of inflammation-related symptoms in multiple organs such as destructive polyarthritis, enthesitis, and gut inflammation [25–29]. Aside from the transmembrane TNF mouse model that develops some degree of new bone formation, none of the previous models have this phenotype. While IL27RA−/− p53R172H/+ mouse model described here is different from the above-mentioned models, it also complements the already known mouse models as it develops primary bone loss and pathological new bone formation associated with minimal or no inflammation in these aged mice. Furthermore, it suggests that these relationships are dissociated, meaning that bone loss and pathological new bone formation can occur in the absence of inflammation. Another advantage of this model is that we can manipulate which signals contribute to bone loss (IL27RA−/−) or ossification of cartilage (mutant p53), therefore making it a useful tool to investigate how these two processes are
...interrelated or finding better drugable targets. Other strengths emerging from this model are that we can monitor in a timely fashion when each of these pathological processes starts to occur, with bone loss and ossification of the cartilage within the intervertebral disc starting as early as age 4 months and progressing with age.

Here, we present evidence in vivo that IL-27 could have a protective role in axial spondyloarthropathies. The protective role of IL-27 strongly supports the findings of other related chronic inflammatory models such as human RA. Briefly, IL-27 potently inhibits human osteoclastogenesis by acting on the osteoclast precursor [7]. Mechanistically, IL-27 could exert these protective effects based on the inhibition of Th17 lineage commitment [10]. Indeed, although Th17 has been closely linked to the pathogenesis of spondyloarthropathies in patients, IL-27 has been shown to exert protective effects in a mouse model of collagen-induced arthritis [4], which is a Th17-dependent inflammatory event, but not in adjuvant or proteoglycan-induced arthritis, which are considered Th1-related events [30, 31]. And lastly, since both IL27 and p53 negatively regulate IL17 levels, we speculate that heightened levels of IL17 may be involved in our model [19].

**Acknowledgments**

The authors are thankful to Keith Michel for offering his technical expertise in micro-CT images. This study was supported by NIH R01 CA120985.

**Author Contributions**

- **Conceptualization**: Denada Dibra, Guillermina Lozano.
- **Data curation**: Xueqing Xia, Mihai Gagea.
- **Formal analysis**: Denada Dibra, Xueqing Xia, Mihai Gagea, Shulin Li.
- **Funding acquisition**: Shulin Li.
- **Investigation**: Xueqing Xia, Mihai Gagea, Shulin Li.
- **Methodology**: Denada Dibra, Xueqing Xia, Mihai Gagea.
- **Project administration**: Denada Dibra, Shulin Li.
Resources: Guillermina Lozano, Shulin Li.

Supervision: Denada Dibra, Guillermina Lozano.

Validation: Denada Dibra.

Visualization: Denada Dibra.

Writing – original draft: Denada Dibra, Shulin Li.

Writing – review & editing: Denada Dibra, Shulin Li.

References

1. Tran TM, Dorris ML, Satumtir a N, Richardson JA, Hammer RE, Shang J, et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum. 2006; 54(4):1317–27. https://doi.org/10.1002/art.21740 PMID: 16575857.

2. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthritis by acting on ROR-gamma(+) CD3(+)CD4(-)CD8(-) entheseal resident T cells. Nature Medicine. 2012; 18(7):1069–+. https://doi.org/10.1038/nm.2817 PubMed PMID: WOS:000306121600036. PMID: 22772566.

3. Adamopoulos IE, Pflanz S. The emerging role of Interleukin 27 in inflammatory arthritis and bone destruction. Cytokine Growth Factor Rev. 2013; 24(2):115–21. https://doi.org/10.1016/j.cytofgfr.2012.10.001 PMID: 23165310; PubMed Central PMCID: PMCPMC3605270.

4. Moon SJ, Park JS, Heo YJ, Kang CM, Kim EK, Lim MA, et al. In vivo action of IL-27: reciprocal regulation of Th17 and Treg cells in collagen-induced arthritis. Exp Mol Med. 2013; 45:e46. https://doi.org/10.1038/em.2013.89 PMID: 24091748; PubMed Central PMCID: PMCPMC3809362.

5. Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol. 2004; 173(2):1171–8. PMID: 15240707.

6. Cao Y, Doodes PD, Giant TT, Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol. 2008; 180(2):922–30. PMID: 18178332.

7. Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkov LB. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum. 2010; 62(2):402–13. https://doi.org/10.1002/art.27200 PMID: 20112358; PubMed Central PMCID: PMCPMC2822027.

8. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthritis by acting on ROR-gamma(+)-CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012; 18(7):1069–76. https://doi.org/10.1038/nm.2817 PMID: 22772566.

9. Yang J, Yang M, Htut TM, Ouyang X, Hanidu A, Li X, et al. Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma T. Eur J Immunol. 2008; 38(5):1204–14. https://doi.org/10.1002/eji.200838145 PMID: 18412165; PubMed Central PMCID: PMCPMC289250.

10. Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol. 2009; 182(9):5748–56. https://doi.org/10.4049/jimmunol.0801162 PMID: 19380822.

11. McHugh J. Spondyloarthropathies: Targeting IL-17 in refractory PsA. Nat Rev Rheumatol. 2017; 13(7):390. https://doi.org/10.1038/nrrheum.2017.94 PMID: 28592895.

12. Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017; 389(10086):2317–27. https://doi.org/10.1016/S0140-6736(17)31429-0 PMID: 28551073.

13. Batten M, Li J, Yi S, Klijavin NM, Danilenko DM, Lucas S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006; 7(9):929–36. https://doi.org/10.1038/nijm.2006167.

14. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-Frequency Developmental Abnormalities in P53-Deficient Mice. Curr Biol. 1995; 5(8):331–6. https://doi.org/10.1016/S0960-9822(95)00183-7 PubMed PMID: WOS:A1995RN56900022. PMID: 7593151

15. Wang XY, Kua HY, Hu YY, Guo K, Zeng Q, Wu Q, et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol. 2006; 172
Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE, et al. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol. 2006; 172(6):909–21. https://doi.org/10.1083/jcb.200508130 PubMed PMID: WOS:000235971900016. PMID: 16533949

Lozano G. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev. 2007; 17(1):66–70. https://doi.org/10.1016/j.gde.2006.12.003 PMID: 17208429.

Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119(6):861–72. https://doi.org/10.1016/j.cell.2004.11.006 PMID: 15607981.

Zhang S, Zheng M, Kibe R, Huang Y, Marrero S, Warren S, et al. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J. 2011; 25(7):2387–98. https://doi.org/10.1096/fj.10-175299 PMID: 21471252; PubMed Central PMCID: PMCPMC3114529.

Bankson JA, Ji L, Ravoori M, Han L, Kundra V. Echo-planar imaging for MRI evaluation of intrathoracic tumors in murine models of lung cancer. J Mag Reson Imaging. 2008; 27(1):57–62. https://doi.org/10.1002/jmri.21221 PMID: 18058933.

van Duivenvoorde LM, Dorris ML, Satumtira N, van Tok MN, Redlich K, van Duysen J, et al. Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human beta(2)-microglobulin-transgenic rat model of spondylarthritits. Arthritis Rheum-U. 2012; 64(10):3210–9. https://doi.org/10.1002/art.34600 PubMed PMID: WOS:000309403000019. PMID: 22736144.

Gupta R, Sharma A, Aroa A, Angrish AK, Gupta A, Tiwari SC. Membranous glomerulonephritis in a patient with ankylosing spondylitis: a rare association. Clin Exp Nephrol. 2009; 13(6):667–70. https://doi.org/10.1007/s10157-009-0217-z PubMed PMID: WOS:000272426400017. PMID: 19652903.

Edwards CK, Bendele AM, Reznikov LI, Fantuzzi G, Chlipala ES, Li L, et al. Soluble human p55 and p75 tumor necrosis factor receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane tumor necrosis factor alpha. Arthritis Rheum-U. 2006; 54(9):2872–85. https://doi.org/10.1002/art.22077 PubMed PMID: WOS:000208729000018. PMID: 16947419.

Phillips KLE, Jordan-Mahy N, Nicklin MJH, Le Maître CL. Interleukin-1 receptor antagonist deficient mice provide insights into pathogenesis of human intervertebral disc degeneration. Ann Rheum Dis. 2013; 72(11):1860–7. https://doi.org/10.1136/annrheumdis-2012-202266 PubMed PMID: WOS:000325532200023. PMID: 23396662.

Horai R, Saio S, Tanioka M, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000; 191(2):313–20. https://doi.org/10.1084/jem.191.2.313 PubMed PMID: WOS:000084908000011. PMID: 10697275.

Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. Journal of Immunology. 2004; 173(2):1171–8. PubMed PMID: WOS:000222621000053.

Cao YX, Doodye PD, Glant TT, Finnegan A. IL-27 induces a TH1 immune response and susceptibility to experimental arthritis. Journal of Immunology. 2008; 180(2):922–30. PubMed PMID: WOS:000222900000029.